Atara Biotherapeutics (NASDAQ:ATRA) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report sent to investors on Tuesday morning,Benzinga reports.

A number of other equities research analysts have also recently issued reports on ATRA. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. RODMAN&RENSHAW cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Canaccord Genuity Group dropped their target price on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. Finally, Rodman & Renshaw began coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $8.36 on Tuesday. Atara Biotherapeutics has a 52-week low of $5.40 and a 52-week high of $39.50. The stock has a market cap of $48.15 million, a price-to-earnings ratio of -0.32 and a beta of 0.51. The firm has a fifty day moving average of $11.83 and a 200-day moving average of $9.94.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the company posted ($16.50) EPS. On average, sell-side analysts predict that Atara Biotherapeutics will post -9.86 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in ATRA. Geode Capital Management LLC boosted its stake in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the last quarter. State Street Corp boosted its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the last quarter. FMR LLC boosted its stake in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $79,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $53,000. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.